Mechanism-based PK-PD models differ from conventional PK-PD models in that they
contain specific expressions to characterize, in a quantitative manner, processes on the …

Docetaxel belongs to the class of taxane antineoplastic agents that act by inducing
microtubular stability and disrupting the dynamics of the microtubular network. The drug has …

In recent years, pharmacokinetic/pharmacodynamic (PK/PD) modeling has developed from
an empirical descriptive discipline into a mechanistic science that can be applied at all …

Breast cancer stem cells (BCSCs), which can fully recapitulate the tumor origin and are often
resistant to chemotherapy and radiotherapy, are currently considered as a major obstacle for …

Purpose: Paclitaxel and carboplatin are frequently used in advanced ovarian cancer
following cytoreductive surgery. Threshold models have been used to predict paclitaxel …

Anthracyclines are used to treat solid and haematological cancers, particularly breast
cancers, lymphomas and childhood cancers. Myelosuppression and cardiotoxicity are the …

Cytotoxic chemotherapy is characterised by a low therapeutic index and significant
variability in therapeutic and toxic effects. In an attempt to reduce this variability, most …

Abstract Irinotecan (CPT-11) is a drug used against a wide variety of tumors, which can
cause severe toxicity, possibly leading to the delay or suspension of the cycle, with the …

Purpose: Cancer chemotherapy, although based on body surface area, often causes
unpredictable myelosuppression, especially severe neutropenia. The aim of this study was …

Purpose: Docetaxel pharmacokinetic (PK) parameters, notably clearance and exposure
(AUC), are characterized by large interindividual variability. The purpose of this study was to …